Table 2. Diagnostic and treatment characteristics of patients with a NSCLC in the DLCA-L in 2016 (N=3,502).
| Variables | N | % |
|---|---|---|
| Diagnostic | ||
| Pathologic proven disease | ||
| No | 573 | 16.4 |
| Unknown | 62 | 1.8 |
| Yes, with: | 2,867 | 81.9 |
| Histology | 1,566 | 54.6 |
| Cytology | 899 | 31.4 |
| Unknown | 402 | 14.0 |
| Invasive diagnostics^ | ||
| Transthoracic punction^ | 948 | 27.1 |
| EUS and/or EBUS^ | 985 | 28.1 |
| Mediastinoscopy^ | 228 | 6.5 |
| Molecular diagnostics | ||
| No/unknown | 2,129 | 60.8 |
| Yes | 1,373 | 39.2 |
| Which successful | 1,310 | 95.4 |
| Treatment | ||
| Treatment goal | ||
| Curative | 1,449 | 41.4 |
| Palliative with active anti-tumour treatment | 901 | 25.7 |
| Palliative without active anti-tumour treatment | 886 | 25.3 |
| Unknown | 266 | 7.6 |
| Initial treatment plan (n=2,350) | ||
| Surgery (combined with other therapy) | 615 | 26.2 |
| Radiotherapy (combined with other non-surgical therapy) | 933 | 39.7 |
| Systematic treatment* only | 618 | 26.3 |
| Different | 145 | 6.2 |
| Unknown | 39 | 1.7 |
^, in case of the invasive diagnostic techniques, only the “yes” option is shown, therefore, the total does not add up to 100%; *, includes: chemotherapy, immunotherapy, targeted therapy. EUS, endoesophageal ultrasound; EBUS, endobronchial ultrasound; DLCA, Dutch Lung Cancer Audit; L, lung-oncologists.